ESCRS - FP16.09 - Effectiveness And Safety Of Xen-45 Gel Stent Implantation In Patients With Open-Angle Glaucoma: Two-Year Results

Effectiveness And Safety Of Xen-45 Gel Stent Implantation In Patients With Open-Angle Glaucoma: Two-Year Results

Published 2023 - 41st Congress of the ESCRS

Reference: FP16.09 | Type: Free paper | DOI: 10.82333/t9e8-hm91

Authors: Armin Motaabbed* 1 , Maria-Laura Waldenberger 1 , Stefan Palkovits 1 , Ana Prinz 1 , Cornelia Hirn 1 , Oliver Findl 1

1Department of Ophthalmology,Hanusch Hospital,Vienna,Austria

Purpose

The XEN Gel Stent is an ab-interno implanted stent, that can be performed in combination with cataract surgery or as a singular procedure. The purpose of this retrospective study was to compare the effectiveness and safety of the XEN 45 Gel Stent between patients with open-angle glaucoma after a two year follow up period.

Setting

All patients included in this study were recruited at the Department of Ophthalmology at Hanusch Hospital in Vienna.  

Methods

Seventy-eight patients with open-angle glaucoma who underwent Xen-45 gel stent implantation at Hanusch hospital during 2017-2020 were included. Clinical information was obtained, including IOP at different visits (preoperative, 1 day-, 1 week-, 1 mo-, 3 mo-, 6 mo-, 1 year-, 2 years postoperative), number of IOP-lowering medications, intra-/postoperative complications, and secondary surgical interventions.

Results

The preoperative mean IOP was 21.4±7.1mmHg, which decreased to 14±5.4mmHg and 13.6±2.5mmHg, one and two years after surgery, respectively. The reduction in mean IOP after one year was 7.3mmHg and 7.7mmHg after two years. The number of IOP-lowering medication decreased consecutively from 2.4±1.6mmHg preoperatively to 1.4±1.6 mmHg one year and to 0.7±1.4mmHg two years postoperatively.

Conclusions

This study demonstrated significant IOP lowering as well as reduction of IOP-lowering medication postoperatively for patients with primary and secondary open angle glaucoma after Xen-45 stent implantation.